 intrapleur cisplatin cytarabin manag malign pleural effus lung cancer studi group trial malign pleural effus common signific problem patient advanc malign pleurodesi tetracyclin agent usual treatment malign pleural effus contrast approach intrapleur chemotherapi potenti advantag underli malign addit effus intracavitari cisplatin-bas chemotherapi cytotox safe effect intraperiton rout ovarian cancer malign mesothelioma littl previou experi intrapleur cisplatin-bas chemotherapi part plan seri trial malign mesothelioma lung cancer studi group intrapleur cisplatin cytarabin patient malign pleural effus varieti solid tumor april novemb patient symptomat untreat malign pleural effus studi singl dose cisplatin cytarabin mg pleural space chest tube patient toxic respons hour week recurr effus complet respons CR partial respons PR decreas amount effus serial chest radiograph patient revers grade renal toxic patient hematolog toxic patient cardiopulmonari toxic overal respons rate CR PR week patient median length respons month CR month PR outcom trial regimen subsequ trial malign pleural mesothelioma